53.23
price down icon0.28%   -0.15
after-market 시간 외 거래: 53.30 0.07 +0.13%
loading
전일 마감가:
$53.38
열려 있는:
$52.57
하루 거래량:
9.31M
Relative Volume:
0.53
시가총액:
$180.46B
수익:
$45.45B
순이익/손실:
$16.18B
주가수익비율:
14.67
EPS:
3.6297
순현금흐름:
$8.96B
1주 성능:
-5.10%
1개월 성능:
-10.60%
6개월 성능:
-13.16%
1년 성능:
-54.01%
1일 변동 폭
Value
$52.38
$53.46
1주일 범위
Value
$52.38
$56.23
52주 변동 폭
Value
$45.05
$115.26

노보 노디스크 Stock (NVO) Company Profile

Name
명칭
Novo Nordisk Adr
Name
전화
-
Name
주소
-
Name
직원
78,387
Name
트위터
@novonordisk
Name
다음 수익 날짜
2024-12-06
Name
최신 SEC 제출 서류
Name
NVO's Discussions on Twitter

NVO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
53.23 243.41B 45.45B 16.18B 8.96B 3.6297
Drug Manufacturers - General icon
LLY
Lilly Eli Co
821.04 716.78B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
192.47 462.11B 92.15B 25.12B 18.18B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
228.25 408.76B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
131.64 254.25B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.18 218.86B 63.43B 16.42B 14.72B 6.4861

노보 노디스크 Stock (NVO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-10-01 업그레이드 HSBC Securities Hold → Buy
2025-09-29 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2025-09-17 업그레이드 Berenberg Hold → Buy
2025-09-16 업그레이드 Rothschild & Co Redburn Neutral → Buy
2025-09-09 업그레이드 Bernstein Mkt Perform → Outperform
2025-08-13 업그레이드 BNP Paribas Exane Underperform → Neutral
2025-08-05 다운그레이드 UBS Buy → Neutral
2025-07-31 다운그레이드 HSBC Securities Buy → Hold
2025-07-30 다운그레이드 Barclays Overweight → Equal Weight
2025-04-17 다운그레이드 BMO Capital Markets Outperform → Market Perform
2025-03-13 업그레이드 Kepler Hold → Buy
2025-03-03 다운그레이드 Stifel Buy → Hold
2025-02-12 개시 Morgan Stanley Equal-Weight
2025-01-06 업그레이드 Bernstein Underperform → Mkt Perform
2024-05-30 개시 Goldman Buy
2024-04-12 개시 BMO Capital Markets Outperform
2024-01-23 개시 Morgan Stanley Overweight
2024-01-16 재개 UBS Neutral
2023-12-01 개시 Cantor Fitzgerald Overweight
2023-10-02 개시 Argus Buy
2023-07-14 개시 HSBC Securities Buy
2022-07-15 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-06-28 다운그레이드 UBS Neutral → Sell
2022-06-27 업그레이드 Exane BNP Paribas Underperform → Neutral
2022-06-07 업그레이드 JP Morgan Neutral → Overweight
2022-05-31 업그레이드 Guggenheim Neutral → Buy
2022-04-25 업그레이드 Cowen Market Perform → Outperform
2022-04-12 업그레이드 Morgan Stanley Underweight → Equal-Weight
2022-03-16 업그레이드 Deutsche Bank Hold → Buy
2022-01-25 다운그레이드 Liberum Hold → Sell
2021-12-20 다운그레이드 JP Morgan Overweight → Neutral
2021-12-17 다운그레이드 Deutsche Bank Buy → Hold
2021-01-20 다운그레이드 Credit Suisse Outperform → Neutral
2021-01-15 개시 Deutsche Bank Buy
2020-09-29 개시 Berenberg Hold
2020-07-06 다운그레이드 BofA Securities Buy → Neutral
2020-05-11 다운그레이드 UBS Buy → Neutral
2020-05-04 개시 Cowen Market Perform
2020-03-16 업그레이드 BofA/Merrill Neutral → Buy
2020-01-03 다운그레이드 Guggenheim Buy → Neutral
2019-11-18 업그레이드 Barclays Equal Weight → Overweight
2019-09-17 업그레이드 Citigroup Neutral → Buy
2019-08-30 다운그레이드 Jefferies Hold → Underperform
2019-06-20 다운그레이드 Deutsche Bank Buy → Hold
2019-06-11 업그레이드 Barclays Underweight → Equal Weight
2019-04-29 업그레이드 Credit Suisse Neutral → Outperform
2019-01-29 개시 Exane BNP Paribas Outperform
2018-12-11 재개 Jefferies Hold
2018-10-09 개시 Guggenheim Buy
2017-12-29 업그레이드 JP Morgan Underweight → Neutral
2017-12-06 업그레이드 BofA/Merrill Neutral → Buy
2017-12-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2017-09-25 다운그레이드 Exane BNP Paribas Outperform → Neutral
2017-09-06 업그레이드 BofA/Merrill Underperform → Neutral
모두보기

노보 노디스크 주식(NVO)의 최신 뉴스

pulisher
09:22 AM

Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership - Benzinga

09:22 AM
pulisher
Oct 22, 2025

Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail

Oct 22, 2025
pulisher
Oct 22, 2025

Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail

Oct 22, 2025
pulisher
Oct 18, 2025

J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Oct 18, 2025
pulisher
Oct 16, 2025

What's Driving the Market Sentiment Around Novo Nordisk AS? - Sahm

Oct 16, 2025
pulisher
Oct 16, 2025

Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' - Sahm

Oct 16, 2025
pulisher
Oct 15, 2025

Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Sahm

Oct 15, 2025
pulisher
Oct 13, 2025

ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView

Oct 13, 2025
pulisher
Oct 11, 2025

Does Novo Nordisk’s Latest Drug Trial Setback Signal a Chance for Investors in 2025? - Sahm

Oct 11, 2025
pulisher
Oct 11, 2025

Deutsche Bank Remains a Buy on Novo Nordisk (0QIU) - The Globe and Mail

Oct 11, 2025
pulisher
Oct 09, 2025

Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Sahm

Oct 09, 2025
pulisher
Oct 04, 2025

UBS Sticks to Their Hold Rating for Novo Nordisk (0QIU) - The Globe and Mail

Oct 04, 2025
pulisher
Oct 02, 2025

BMO Capital Remains a Hold on Novo Nordisk (NVO) - The Globe and Mail

Oct 02, 2025
pulisher
Oct 01, 2025

J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU) - The Globe and Mail

Oct 01, 2025
pulisher
Sep 30, 2025

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - sharewise.com

Sep 30, 2025
pulisher
Sep 30, 2025

Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Sep 30, 2025
pulisher
Sep 28, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa

Sep 28, 2025
pulisher
Sep 27, 2025

Novo Nordisk ADR earnings missed, revenue topped estimates - Investing.com India

Sep 27, 2025
pulisher
Sep 24, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO | FinancialContent - FinancialContent

Sep 24, 2025
pulisher
Sep 24, 2025

NVO Stock Quote Price and Forecast - CNN

Sep 24, 2025
pulisher
Sep 23, 2025

NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 23, 2025
pulisher
Sep 20, 2025

NVO IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.

Sep 20, 2025
pulisher
Sep 19, 2025

Tools to assess Novo Nordisk A s (b Shares) Adrhedged’s risk profileJuly 2025 Setups & Technical Pattern Based Buy Signals - newser.com

Sep 19, 2025
pulisher
Sep 19, 2025

Deutsche Bank Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail

Sep 19, 2025
pulisher
Sep 18, 2025

Novo Nordisk And Prudential Stand Out In European ADR Gains - Finimize

Sep 18, 2025
pulisher
Sep 18, 2025

Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Sahm

Sep 18, 2025
pulisher
Sep 18, 2025

Custom strategy builders for tracking Novo Nordisk A s (b Shares) AdrhedgedStock Surge & AI Forecasted Entry/Exit Points - newser.com

Sep 18, 2025

노보 노디스크 (NVO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$292.89
price down icon 1.04%
$120.74
price down icon 0.59%
drug_manufacturers_general MRK
$87.18
price down icon 0.49%
drug_manufacturers_general PFE
$24.67
price down icon 0.20%
drug_manufacturers_general SNY
$49.52
price down icon 0.94%
자본화:     |  볼륨(24시간):